Calibration of the NuSTAR High Energy Focusing X-ray Telescope

We present the calibration of the \textit{Nuclear Spectroscopic Telescope Array} (\nustar) X-ray satellite. We used the Crab as the primary effective area calibrator and constructed a piece-wise linear spline function to modify the vignetting response. The achieved residuals for all off-axis angles and energies, compared to the assumed spectrum, are typically better than $\pm 2$\% up to 40\,keV and 5--10\,\% above due to limited counting statistics. An empirical adjustment to the theoretical 2D point spread function (PSF) was found using several strong point sources, and no increase of the PSF half power diameter (HPD) has been observed since the beginning of the mission. We report on the detector gain calibration, good to 60\,eV for all grades, and discuss the timing capabilities of the observatory, which has an absolute timing of $\pm$ 3\,ms. Finally we present cross-calibration results from two campaigns between all the major concurrent X-ray observatories (\textit{Chandra}, \textit{Swift}, \textit{Suzaku} and \textit{XMM-Newton}), conducted in 2012 and 2013 on the sources 3C\,273 and PKS\,2155-304, and show that the differences in measured flux is within $\sim$10\% for all instruments with respect to \nustar

NuSTAR Spectroscopy of Multi-Component X-ray Reflection from NGC 1068

We report on observations of NGC1068 with NuSTAR, which provide the best constraints to date on its $>10$~keV spectral shape. We find no strong variability over the past two decades, consistent with its Compton-thick AGN classification. The combined NuSTAR, Chandra, XMM-Newton, and Swift-BAT spectral dataset offers new insights into the complex reflected emission. The critical combination of the high signal-to-noise NuSTAR data and a spatial decomposition with Chandra allow us to break several model degeneracies and greatly aid physical interpretation. When modeled as a monolithic (i.e., a single N_H) reflector, none of the common Compton-reflection models are able to match the neutral fluorescence lines and broad spectral shape of the Compton reflection. A multi-component reflector with three distinct column densities (e.g., N_H~1.5e23, 5e24, and 1e25 cm^{-2}) provides a more reasonable fit to the spectral lines and Compton hump, with near-solar Fe abundances. In this model, the higher N_H components provide the bulk of the Compton hump flux while the lower N_H component produces much of the line emission, effectively decoupling two key features of Compton reflection. We note that ~30% of the neutral Fe Kalpha line flux arises from >2" (~140 pc), implying that a significant fraction of the <10 keV reflected component arises from regions well outside of a parsec-scale torus. These results likely have ramifications for the interpretation of poorer signal-to-noise observations and/or more distant objects [Abridged].Comment: Submitted to ApJ; 23 pages (ApJ format); 11 figures and 3 tables; Comments welcomed

Peering through the Dust: NuSTAR Observations of Two FIRST-2MASS Red Quasars

Some reddened quasars appear to be transitional objects in the merger-induced black hole growth/galaxy evolution paradigm, where a heavily obscured nucleus starts to be unveiled by powerful quasar winds evacuating the surrounding cocoon of dust and gas. Hard X-ray observations are able to peer through this gas and dust, revealing the properties of circumnuclear obscuration. Here, we present NuSTAR and XMM-Newton/Chandra observations of FIRST-2MASS selected red quasars F2M 0830+3759 and F2M 1227+3214. We find that though F2M 0830+3759 is moderately obscured (N_(H,Z) = 2.1 ± 0.2 × 10^(22) cm^(−2)) and F2M 1227+3214 is mildly absorbed (N_(H,Z) = 3.4^(+0.8)_(−0.7) × 10^(21) cm^(−2)) along the line-of-sight, heavier global obscuration may be present in both sources, with N_(H,S) = 3.7^(+4.1)_(−2.6) × 10^(23) cm^(−2) and < 5.5 × 10^(23) cm^(−2), for F2M 0830+3759 and F2M 1227+3214, respectively. F2M 0830+3759 also has an excess of soft X-ray emission below 1 keV which is well accommodated by a model where 7% of the intrinsic AGN X-ray emission is scattered into the line-of-sight. While F2M 1227+3214 has a dust-to-gas ratio (E(B − V )/N_H) consistent with the Galactic value, the E(B−V )/NH value for F2M 0830+3759 is lower than the Galactic standard, consistent with the paradigm that the dust resides on galactic scales while the X-ray reprocessing gas originates within the dust-sublimation zone of the broad-line-region. The X-ray and 6.1μm luminosities of these red quasars are consistent with the empirical relations derived for high-luminosity, unobscured quasars, extending the parameter space of obscured AGN previously observed by NuSTAR to higher luminosities

3C 273 with NuSTAR: Unveiling the Active Galactic Nucleus

We present results from a 244 ks NuSTAR observation of 3C 273 obtained during a cross-calibration campaign with the Chandra, INTEGRAL, Suzaku, Swift, and XMM-Newton observatories. We show that the spectrum, when fit with a power-law model using data from all observatories except INTEGRAL over the 1–78 keV band, leaves significant residuals in the NuSTAR data between 30 and 78 keV. The NuSTAR 3–78 keV spectrum is well described by an exponentially cutoff power law (Γ = 1.646 ± 0.006, E_(cutoff) = 202_(-34)^(+51) keV) with a weak reflection component from cold, dense material. There is also evidence for a weak (EW = 23 ± 11 eV) neutral iron line. We interpret these features as arising from coronal emission plus reflection off an accretion disk or distant material. Beyond 80 keV INTEGRAL data show clear excess flux relative to an extrapolation of the active galactic nucleus model fit to NuSTAR. This high-energy power law is consistent with the presence of a beamed jet, which begins to dominate over emission from the inner accretion flow at 30–40 keV. Modeling the jet locally (in the NuSTAR + INTEGRAL band) as a power law, we find that the coronal component is fit by Γ_(AGN) = 1.638 ± 0.045, E_(cutoff) = 47 ± 15 keV, and jet photon index by Γ_(jet) = 1.05 ± 0.4. We also consider Fermi/LAT observations of 3C 273, and here the broadband spectrum of the jet can be described by a log-parabolic model, peaking at ~2 MeV. Finally, we investigate the spectral variability in the NuSTAR band and find an inverse correlation between flux and Γ

The variable hard x-ray emission of NGC 4945 as observed by NUSTAR

We present a broadband (~0.5-79 keV) spectral and temporal analysis of multiple NuSTAR observations combined with archival Suzaku and Chandra data of NGC4945, the brightest extragalactic source at 100 keV. We observe hard X-ray (> 10 keV) flux and spectral variability, with flux variations of a factor 2 on timescales of 20 ksec. A variable primary continuum dominates the high energy spectrum (>10 keV) in all the states, while the reflected/scattered flux which dominates at E< 10 keV stays approximately constant. From modelling the complex reflection/transmission spectrum we derive a Compton depth along the line of sight of tau_Thomson ~ 2.9, and a global covering factor for the circumnuclear gas of ~ 0.15. This agrees with the constraints derived from the high energy variability, which implies that most of the high energy flux is transmitted, rather that Compton-scattered. This demonstrates the effectiveness of spectral analysis in constraining the geometric properties of the circumnuclear gas, and validates similar methods used for analyzing the spectra of other bright, Compton-thick AGN. The lower limits on the e-folding energy are between 200-300 keV, consistent with previous BeppoSAX, Suzaku and Swift BAT observations. The accretion rate, estimated from the X-ray luminosity and assuming a bolometric correction typical of type 2 AGN, is in the range ~0.1-0.3 lambda_Edd depending on the flux state. The substantial observed X-ray luminosity variability of NGC4945 implies that large errors can arise from using single-epoch X-ray data to derive L/L_Edd values for obscured AGNs.Comment: Accepted for publication in Ap

Estrogen/progesterone Receptor and HER2 Discordance Between Primary Tumor and Brain Metastases in Breast Cancer and Its Effect on Treatment and Survival

BACKGROUND: Breast cancer treatment is based on estrogen receptors (ERs), progesterone receptors (PRs), and human epidermal growth factor receptor 2 (HER2). At the time of metastasis, receptor status can be discordant from that at initial diagnosis. The purpose of this study was to determine the incidence of discordance and its effect on survival and subsequent treatment in patients with breast cancer brain metastases (BCBM). METHODS: A retrospective database of 316 patients who underwent craniotomy for BCBM between 2006 and 2017 was created. Discordance was considered present if the ER, PR, or HER2 status differed between the primary tumor and the BCBM. RESULTS: The overall receptor discordance rate was 132/316 (42%), and the subtype discordance rate was 100/316 (32%). Hormone receptors (HR, either ER or PR) were gained in 40/160 (25%) patients with HR-negative primary tumors. HER2 was gained in 22/173 (13%) patients with HER2-negative primary tumors. Subsequent treatment was not adjusted for most patients who gained receptors-nonetheless, median survival (MS) improved but did not reach statistical significance (HR, 17-28 mo, P = 0.12; HER2, 15-19 mo, P = 0.39). MS for patients who lost receptors was worse (HR, 27-18 mo, P = 0.02; HER2, 30-18 mo, P = 0.08). CONCLUSIONS: Receptor discordance between primary tumor and BCBM is common, adversely affects survival if receptors are lost, and represents a missed opportunity for use of effective treatments if receptors are gained. Receptor analysis of BCBM is indicated when clinically appropriate. Treatment should be adjusted accordingly. KEY POINTS: 1. Receptor discordance alters subtype in 32% of BCBM patients.2. The frequency of receptor gain for HR and HER2 was 25% and 13%, respectively.3. If receptors are lost, survival suffers. If receptors are gained, consider targeted treatment

The GAPS experiment to search for dark matter using low-energy antimatter

© Copyright owned by the author(s) under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives 4.0 International License (CC BY-NC-ND 4.0). The GAPS experiment is designed to carry out a sensitive dark matter search by measuring low-energy cosmic ray antideuterons and antiprotons. GAPS will provide a new avenue to access a wide range of dark matter models and masses that is complementary to direct detection techniques, collider experiments and other indirect detection techniques. Well-motivated theories beyond the Standard Model contain viable dark matter candidates which could lead to a detectable signal of antideuterons resulting from the annihilation or decay of dark matter particles. The dark matter contribution to the antideuteron flux is believed to be especially large at low energies (E < 1 GeV), where the predicted flux from conventional astrophysical sources (i.e. from secondary interactions of cosmic rays) is very low. The GAPS low-energy antiproton search will provide stringent constraints on less than 10 GeV dark matter, will provide the best limits on primordial black hole evaporation on Galactic length scales, and will explore new discovery space in cosmic ray physics. Unlike other antimatter search experiments such as BESS and AMS that use magnetic spectrometers, GAPS detects antideuterons and antiprotons using an exotic atom technique. This technique, and its unique event topology, will give GAPS a nearly background-free detection capability that is critical in a rare-event search. GAPS is designed to carry out its science program using long-duration balloon flights in Antarctica. A prototype instrument was successfully flown from Taiki, Japan in 2012. GAPS has now been approved by NASA to proceed towards the full science instrument, with the possibility of a first long-duration balloon flight in late 2020. This presentation will motivate low-energy cosmic ray antimatter searches and it will discuss the current status of the GAPS experiment and the design of the payload

Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient.

PurposeConventional wisdom has rendered patients with brain metastases ineligible for clinical trials for fear that poor survival could mask the benefit of otherwise promising treatments. Our group previously published the diagnosis-specific Graded Prognostic Assessment (GPA). Updates with larger contemporary cohorts using molecular markers and newly identified prognostic factors have been published. The purposes of this work are to present all the updated indices in a single report to guide treatment choice, stratify research, and define an eligibility quotient to expand eligibility.MethodsA multi-institutional database of 6,984 patients with newly diagnosed brain metastases underwent multivariable analyses of prognostic factors and treatments associated with survival for each primary site. Significant factors were used to define the updated GPA. GPAs of 4.0 and 0.0 correlate with the best and worst prognoses, respectively.ResultsSignificant prognostic factors varied by diagnosis and new prognostic factors were identified. Those factors were incorporated into the updated GPA with robust separation (P &lt; .01) between subgroups. Survival has improved, but varies widely by GPA for patients with non-small-cell lung, breast, melanoma, GI, and renal cancer with brain metastases from 7-47 months, 3-36 months, 5-34 months, 3-17 months, and 4-35 months, respectively.ConclusionMedian survival varies widely and our ability to estimate survival for patients with brain metastases has improved. The updated GPA (available free at brainmetgpa.com) provides an accurate tool with which to estimate survival, individualize treatment, and stratify clinical trials. Instead of excluding patients with brain metastases, enrollment should be encouraged and those trials should be stratified by the GPA to ensure those trials make appropriate comparisons. Furthermore, we recommend the expansion of eligibility to allow for the enrollment of patients with previously treated brain metastases who have a 50% or greater probability of an additional year of survival (eligibility quotient &gt; 0.50)